Mounjaro Stomach Paralysis Lawsuits

Legally Reviewed

This article has been written and reviewed for legal accuracy and clarity by Lawsuit Legal News' writers and attorneys and is accurate as possible. This content should not be taken as legal advice from attorney.


Lawsuit Legal News does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us. This article should not be taken as advice from an attorney.

Eli Lilly and Company’s Mounjaro is a medication used for glycemic control in Type II diabetics. The tirzepatide drug is one of the most potent GLP-1 RA medications on the market, and its ability to help users achieve considerable weight loss has led some physicians to describe it as the successor of Novo Nordisk’s Ozempic (semaglutide). 

However, despite Mounjaro’s efficacy, the medication can cause various undisclosed side effects such as gastroparesis, also known as stomach paralysis, which has landed uninformed users in hospitals and surgery rooms nationwide. Eli Lilly and Company’s failure to properly inform prescribing physicians and Mounjaro users of these risks has given rise to manifold product liability lawsuits which seek to hold the company accountable. Eli Lilly has not issued any form of recall despite the number of adverse events reported.

Lawsuit Legal News is tracking the various Mounjaro stomach paralysis lawsuits as they advance in federal courts throughout the country and will conduct in-depth analyses of important developments.

We anticipate the Mounjaro class action lawsuit will evolve into multidistrict litigation as these lawsuits are consolidated before one Judge in one jurisdiction.

Eli Lilly and Company’s “Dual Agonist” Medication

Tirzepatide (Mounjaro) is a unique member of the GLP-1 RA drug class which acts as a “dual agonist”, mimicking both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These vital hormones are naturally produced in the small intestine, facilitate the production of insulin, and catalyze the metabolism of sugars. 

Mounjaro (a GLP-1 receptor agonist) is typically prescribed in 5, 10, and 15-milligram dosages, which users inject once a week. The U.S. Food and Drug Administration (FDA) approved Mounjaro for the treatment of Type II diabetes mellitus, because of its effectiveness in regulating blood sugar levels. While Mounjaro falls into the classification of diabetes drugs, it is among the GLP-1 agonists that have been utilized off-label as weight-loss medications.

However, like all GLP-1 RAs, tirzepatide has a considerable impact on the functioning of the digestive tract and gastrointestinal system. For instance, in clinical trials, the FDA observed that Mounjaro users sustained on average greater weight reduction than participants prescribed either a placebo or semaglutide.  Keep in mind that Mounjaro slows the movement of food from the stomach to small intestine which makes the user fell full and satiated longer.

As a result, users throughout the country have sought Mounjaro prescriptions for both chronic weight management and cosmetic weight loss purposes. In an effort to capitalize on the demand, Eli Lilly and Company even developed an alternative tirzepatide medication, Zepbound, for weight loss, which received FDA approval in November 2023. 


Our goal is to provide the most up-to-date information on the Mounjaro lawsuit against Eli Lilly on the Internet. Please bookmark this page and if you should ever need additional information you can reach out to us today at: for assistance in this lawsuit.

February 3, 2024 - Mounjaro Lawsuits Against Eli Lilly Consolidated Into JPML

The Judicial Panel on Multidistrict Litigation has consolidated all lawsuits that have been filed in Federal Courts throughout the United States into one jurisdiction. Mounjaro lawsuits naming Eli Lilly as a defendant along with lawsuits against the manufacturers of Ozempic and Wegovy (Novo Nordisk) have been consolidated before Judge Gene Pratter in the Eastern District of Pennsylvania. There are presently thirteen lawsuits in the Eastern District of Pennsylvania. Transfer orders will be issued to move Ozempic and Mounjaro lawsuits filed in other areas of the nation. 

February 1, 2024 - JPML to Determine Fate of Mounjaro Lawsuit Against Eli Lilly

Legal experts are anticipating a decision regarding whether the Judicial Panel on Multidistrict Litigation will establish an MDL (Multidistrict Litigation) for the Mounjaro lawsuits. We are anticipating an order to be issued in the next forty-eight (48) hours. Once we have more information, our readers will be the first to know.

December 22, 2023 - Mounjaro Lawsuit Filed in Louisiana Can Determine Future of Mounjaro Lawsuits

Another serious lawsuit has been filed against pharmaceutical giants Eli Lilly & Co. and Novo Nordisk by a patient from Louisiana. They claim that Mounjaro and Ozempic were responsible for causing them severe side effects, including cyclical vomiting and tooth loss.

The defendants are currently in the process of contesting the jurisdiction of the Louisiana court, claiming that the lawsuit fails to establish a connection between Louisiana and their companies.

Additionally, they are arguing that the plaintiff's legal team has not shown adequate evidence that relates to Louisiana within the context of the Mounjaro lawsuit.

The plaintiff wants their case to be consolidated with both the potential Ozempic and Mounjaro MDL. The final decision on the MDL will be made on January 25 at the JPML hearing, but it will likely take a week or so to hear the verdict.

December 2, 2023 - Mounjaro Lawyers Petition the JPML to Consolidate Lawsuits Against Eli Lilly

A recent motion has been submitted to the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all cases against Mounjaro (as well as Ozempic and Wegovy, and similar pharmaceuticals) into one case, called a multidistrict litigation or MDL. If this motion is approved, it would force all the federal cases into a single jurisdiction and a single judge in one court. This is done to speed up the cases.

A fresh study, published in the Journal of the American Medical Association (JAMA), has shown a potential increased risk of serious gastrointestinal problems for people using popular weight loss medications like Mounjaro. The study states, "The utilization of GLP-1 agonists for weight loss when compared to the use of bupropion-naltrexone, has been associated with an increased likelihood of experiencing conditions such as pancreatitis, gastroparesis, and bowel obstruction." Over the past year, there have been numerous adverse event reports of gastrointestinal injuries caused by the off-label use of a diabetes drug for weight loss. 

While Eli Lilly has stated that delayed gastric emptying is to be expected, the manufacturer of Mounjaro has yet to acknowledge severe stomach problems and severe gastrointestinal events that have been linked to their prescription medication. 

Our firm presently represents a number of individuals who visited the emergency room for gastroparesis (paralyzed stomach), excessive vomiting, and other severe gastrointestinal issues. While this medication is intended to slow stomach emptying so patients feel full longer, the drug may lead to gastroparesis, wherein the stomach muscles are weakened to the point that food is not moved into the intestines and instead rots in the stomach. 

Sides Effects of Mounjaro 

Eli Lilly and the FDA have disclosed various side effects associated with the long-term use of Mounjaro, which was approved for sale in American markets in 2022. The most common adverse gastrointestinal events which users have reported include nausea, vomiting, and diarrhea. 

Other common side effects of Mounjaro include:

  • Severe Vomiting/Excessive Vomiting
  • Ileus
  • Pancreatitis
  • Renal Complications
  • Abdominal Pain/Severe Stomach Pain
  • Gastrointestinal Issues 
  • Severe Gastroparesis/Delayed Gastric Emptying
  • Gallbladder Issues

Users who experience the symptoms of any of the preceding complications are advised to seek immediate medical assistance and to speak with their physician to determine whether or not to continue the use of Mounjaro.  We have noted the risk of gastroparesis is significant with Mounjaro and other diabetes medications that have been used off-label to treat obesity.  Our clients have consistently reported gastrointestinal side effects.

Tirzepatide Linked to Gastroparesis (Stomach Paralysis)

In recent months, Mounjaro users have reported developing gastroparesis (stomach paralysis) after using the tirzepatide medication for the treatment of Type II diabetes. The debilitating condition occurs when the stomach muscles which deposit contents into the first part of the small intestine slow down altogether. 

This results in various subsequent complications, like: 

  • Profuse vomiting 
  • Dehydration
  • Bloating
  • Stomach pain 

Type II diabetics already are at a heightened risk of developing gastroparesis on account of damage to the vagus nerve, yet Eli Lilly’s popular antidiabetic does not come with a warning label that fully or properly informs users who are predisposed to the condition. The flurry of alarming Mounjaro reports parallels previous claims in investigative journalism conducted by CNN, which exposed the unnerving experiences of Ozempic and Wegovy users and forecasted subsequent litigation. 

GLP-1 RA Medications Known to Cause Gastroparesis and Other Adverse Medical Events

Mounjaro’s rapid success in American markets was partially a result of the novelty of its “dual agonist” design and classification. Prior to Mounjaro’s introduction the antidiabetic and weight management industry had already undergone massive transformations in the wake of Novo Nordisk’s cohort of GLP-1 RA medications, such as: 

  • Rybelsus 
  • Saxenda
  • Ozempic
  • Wegovy 

The Nordic multinational company’s semaglutide drugs soon acquired mythic status, not only for their efficacy in treating Type II diabetes but their marked weight loss potential. Nevertheless, clinical research and FDA postmarketing review have only recently scrutinized the long-term side effects of GLP-1 RA use and discovered highly alarming rates of gastroparesis. 

For example, an October 2023 report in JAMA found that the prescription of GLP-1 RAs for weight loss resulted in an increased incidence rate of stomach paralysis in comparison to available alternatives. The FDA also recently revised Ozempic’s warning label to inform users of the risk of bowel obstruction, an adverse medical event common to most GLP-1 RAs. 

Eli Lilly Failed to Warn Users of Adverse Medical Events

The makers of prescription medications are required to inform users and/or prescribing physicians of the risks associated with a particular product. This duty of care is a critical component of guaranteeing the safety and well-being of the public, and a failure to observe it may constitute an actionable offense, especially if it results in severe injuries. 

Unfortunately, there is no explicit warning or caveat on Mounjaro’s side effects label which informs either prescribing physicians or users of the risk of stomach paralysis. Consequently, plaintiffs in the ongoing Mounjaro stomach paralysis lawsuits allege that they were misled about the safety and efficacy of the “dual agonist” drug and would not have taken it had they known of its potential to cause gastroparesis. 

As of date, the U.S. Food and Drug Administration declined to comment on whether GLP-1 medications such as Ozempic and Mounjaro cause gastroparesis. The FDA changed the warning label in September of 2023, to acknowledge the potential for intestinal blockage (Ileus). However, in light of patient safety, we do not believe off label use of Mounjaro (Tirzepatide) for weight loss The warning label also warns users that Mounjaro delays gastric emptying.

Mounjaro Manufacturer Faces Product Liability Lawsuits 

On account of Eli Lilly and Company’s failure to place the safety of consumers above its concern for profits, Mounjaro users throughout the country have filed lawsuits in an effort to seek accountability and compensation. The cases are part and parcel of nearly 20 GLP-1 RA-related lawsuits that have been filed in federal courts in recent months. 

Prominent law firms representing current plaintiffs have stated that they are actively investigating upwards of 10,000 claims and have initiated the process to consolidate extant cases for pretrial legal proceedings in Louisiana federal court. 

The popularity of GLP-1 medications utilized as weight loss drugs has skyrocketed in recent years. We believe that while the FDA will monitor for potential adverse events if past incidents are any indication of future issues, Mounjaro should not be used for obesity medicine. Physicians should recommend patients take diabetes medications for their intended purpose. 

First Mounjaro Stomach Paralysis Lawsuit Filed in August 2023 

The first Mounjaro and Ozempic stomach paralysis lawsuit was filed in August 2023 against both Novo Nordisk and Eli Lilly and Company. The plaintiff, Jaclyn Bjorklund, claims to have taken Ozempic for slightly more than a year before developing severe gastrointestinal complications reminiscent of stomach paralysis. 

After vomiting so excessively that she lost teeth, Bjorklund discontinued her use of Ozempic and received, upon the recommendation of her physician, a prescription for Mounjaro, in July 2023. However, the new medication, whose gastrointestinal effects are more potent than those of Ozempic, served only to intensify her medical emergency. 

Bjorklund alleges that Novo Nordisk, Ozempic manufacturer, and Eli Lilly and Company failed to adequately warn her of the risks she ran from taking their drugs, which directly caused her injuries. Another Mounjaro lawsuit filed in December 2023 echoed Bjorklund’s complaint. 

The plaintiff, Blake, received a Mounjaro prescription and shortly thereafter suffered from routine bouts of projectile vomiting. Blake’s condition became so severe as to necessitate hospitalization and required him to take time off from work, jeopardizing his household’s financial stability. In order to quell his seemingly permanent stomach paralysis diagnosis, Blake has had to adjust his work schedule, radically alter his diet, and seek alternative medications to treat his Type II diabetes. 

Novo Nordisk and Eli Lilly and Co. Attempt to Dismiss Litigation

Both Novo Nordisk and Eli Lilly and Company have denied liability, reaffirmed the safety of their drugs, and undertaken to derail the litigation. In the final quarter of 2023, both pharmaceutical companies petitioned the federal court in which Bjorklund’s claim had been filed to dismiss her claim on the grounds that she failed to establish specific instances of wrongdoing and sought damages impermissible via the statute under which she filed suit. 

Judge James D. Cain Jr., who currently presides over the lawsuit, largely rejected Novo Nordisk’s arguments and reaffirmed Bjorklund’s standing at the pleading stage. He has not, however, issued a final decision on Eli Lilly and Company’s motion. Nonetheless, given the intentional similarity of the companies’ rationale to dismiss the lawsuit, it is likely that the court will rule comparably on the Mounjaro manufacturer’s bid. 

On December 1, 2023, the law firm representing both Bjorklund and Blake filed a motion with the United States Judicial Panel on Multidistrict Litigation (JPML). The JPML is a federal panel that determines whether or not to consolidate cases for pretrial proceedings. 

The court relies upon various criteria in making a decision, such as commonalities of fact and law, the economy for the resolution of mass torts through the federal court system, and the importance of consistent rulings. If the U.S. JPML concludes that consolidating similar cases would efficiently streamline legal proceedings, eliminate duplicative discovery, and alleviate parties of burdensome costs, it establishes a multidistrict litigation (MDL). 

The JPML has yet to respond to the request to create a Mounjaro MDL, which plaintiffs seek to transfer to the U.S. District Court for the Western District of Louisiana, before Judge Cain. A favorable ruling from the JPML would not only consolidate pending lawsuits but would likely result in an eventual enrollment procedure for novel claims. 

Contact an Experienced Mounjaro Stomach Paralysis Lawyer Today 

Our goal is to inform consumers of defective prescription medications of their rights and legal options and assist them with attaining fair compensation for their damages. That is why our talented legal team is on standby to offer Mounjaro users advice and assistance as they determine whether or not to file a claim against Eli Lilly and Company. 

Over the past several years, we have used our 120 combined years of personal injury law experience to pursue accountability and justice from the makers of Ozempic, Tepezza, and Tylenol. In addition, we are comfortable with managing the complex legal landscape of multidistrict litigation, in order to maximize our clients’ chance of success. 

In a free consultation, our Mounjaro lawyers can answer any additional questions you may have about your eligibility and the compensation to which you may be entitled. For more information, contact us today. We are reviewing claims against Mounjaro and other GLP-1 drugs such as Ozempic and Wegovy. The number of medical issues and severe side effects associated with GLP-1 medications is alarming.

Mounjaro Gastroparesis Lawsuit FAQs

In the 5 months since Bjorklund filed the first Ozempic and Mounjaro stomach paralysis lawsuit, the groundswell of filings and the potential for thousands of claims have increased exponentially. To dispel any confusion, we have answered common questions that prospective plaintiffs and Mounjaro users have raised over the complex process of seeking compensation and accountability for their injuries. 

What Are The Symptoms of Gastroparesis?

  • Nausea
  • Vomiting
  • Abdominal bloating
  • Severe abdominal pain/stomach pain
  • Change in blood sugar levels

Who Can File a Mounjaro Stomach Paralysis Claim?

If you received a Mounjaro prescription and then developed gastroparesis as a side effect of tirzepatide, you may be eligible to file suit against Eli Lilly and Company. In order to establish standing for a stomach paralysis claim, you should preserve any and all:

  • Medical records and prescription information
  • Consultations with your prescribing physician 
  • Diagnoses of a medical condition 
  • Affiliated billings and costs

Secondly, every individual who seeks to file a claim must satisfy the applicable statutes of limitation, which establish a deadline for eligibility. In defective drug cases, the statutes of limitation commonly apply when the users of prescription medications first develop symptoms of an undisclosed disorder or receive a diagnosis from their healthcare providers. 

How Much Is a Mounjaro Lawsuit Worth? 

Determining case value for Mounjaro lawsuits depends upon a multivariable analysis of compensable economic and noneconomic losses a plaintiff has sustained on account of an injury. Ultimately, every compensation figure is uniquely tailored to the circumstances of the plaintiff who requests it.  

Moreover, the state or federal statutes under which plaintiffs file suit determine the scope and extent of available damages. In Bjorklund’s lawsuit, for example, the defendants objected to the request for punitive damages, on the grounds that they were impermissible under the Louisiana Product Liability Act (LPLA). 

Generally speaking, damages in product liability and defective drug litigation include: 

  • Medical costs
  • Out-of-pocket expenses
  • Lost wages and income 
  • Pain and suffering
  • Decreased quality of life
  • Mental anguish 
  • Emotional distress

Should I Seek a Mounjaro Stomach Paralysis Lawyer for My Claim?

We strongly urge prospective plaintiffs to speak with a qualified Mounjaro stomach paralysis lawyer as soon as possible. Given the complexity of legal deadlines, liability questions, and jurisdictional determinations, the expertise of an experienced legal representative can make or break a claim for relief. 

In addition, the assistance of competent legal counsel can alleviate plaintiffs of conducting the arduous tasks of: 

  • Acquiring relevant paperwork 
  • Composing compelling claims
  • Negotiating with recalcitrant defendants

Latest News